MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$14,548K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Non-cash lease expense
    • Accrued expenses and other curre...
    • Other non-current assets
    • Depreciation and amortization ex...
Negative Cash Flow Breakdown
    • Change in fair value of warrant ...
    • Accounts payable
    • Net loss
    • Others
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Loss on disposal of property and equipment
-
-
-
-2
Net loss
-1,174
-9,101
-18,736
-47,964
Depreciation and amortization expense
21
290
229
537
Impairment of long-lived assets
-
1,112
-
-
Non-cash lease expense
185
330
326
508
Stock-based compensation expense
423
1,661
1,424
3,628
Change in fair value of warrant liability
-9,640
-6,429
-2,099
-
Offering costs recognized in other expense, net
-
0
2,046
-
Prepaid expenses and other current assets
195
2,288
209
-718
Other non-current assets
-36
-37
-42
-628
Accounts payable
-3,781
-2,946
1,132
4,007
Accrued expenses and other current liabilities
55
-4,065
-700
391
Operating lease liability
-478
-468
-452
-750
Net cash used in operating activities
-14,548
-21,867
-16,999
-38,295
Purchases of property and equipment
-
0
0
7
Proceeds from sales of property and equipment
-
0
0
12
Proceeds from exercise of common stock options
-
-
-
0
Net cash provided by (used in) investing activities
-
0
0
5
Proceeds from issuance of common stock through atm offering, net
-
0
514
5,940
Proceeds from issuance of common stock and warrants through underwritten offering, net
-
-360
27,874
-
Proceeds from issuance of common stock pursuant to employee stock purchase plan
-
20
0
223
Net cash provided by financing activities
-
-340
28,388
6,163
Net decrease in cash, cash equivalents and restricted cash
-14,548
-22,207
11,389
-32,127
Cash, cash equivalents and restricted cash at beginning of the period
29,109
51,316
72,054
-
Cash, cash equivalents and restricted cash at end of the period
14,561
29,109
51,316
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net decrease incash, cash...-$14,548K Stock-based compensationexpense$423K Non-cash lease expense$185K Accrued expenses andother current...$55K Other non-currentassets-$36K Depreciation andamortization expense$21K Net cash used inoperating activities-$14,548K Canceled cashflow$720K Change in fair value ofwarrant liability-$9,640K Accounts payable-$3,781K Net loss-$1,174K Operating lease liability-$478K Prepaid expenses andother current assets$195K

Jasper Therapeutics, Inc. (JSPRW)

Jasper Therapeutics, Inc. (JSPRW)